



FOR IMMEDIATE RELEASE

Selexis SA to Partner at the BIO 2006 Annual International Convention

Selexis to Participate in the Business Forum's One-on-one Partnering Meetings

Geneva, Switzerland – March 17, 2006 – Selexis SA, a Swiss-based biotechnology company specializing in high yield and stable cell line development for therapeutic proteins announced today that representatives from the Company will be participating in the BIO 2006 Business Forum's Partnering Meetings being held April 10 - 12, 2006 in Chicago, Illinois, at the McCormick Convention Center. Selexis CEO, Dr. Igor Fisch and Dr. Cori Gorman, Head of Business Development will be taking part in the pre-scheduled meetings.

Companies or individuals attending BIO 2006 can schedule meetings with Selexis (registration required) by visiting: <http://business-forum.bio.org/opencms/bf/2006/partnering/index.jsp>.

Selexis Partnering Schedule:

- **Monday, April 10** Business Forum - 8:00 AM - 5:30 PM

McCormick Place, South Building, Hall A2

- **Tuesday, April 11** Business Forum - 8:00 AM - 5:30 PM

McCormick Place, South Building, Hall A2

- **Wednesday, April 12** Business Forum - 8:00 AM - 5:30 PM

McCormick Place, South Building, Hall A2

For companies or individuals not participating in partnering meetings, Selexis will be co-exhibiting with BioAlps at the Switzerland Pavilion in booth number 1133. For the exhibit hall schedule, visit: <http://www.bio.org/events/2006/exhibitors/sched.asp>.

SELEXIS EUROPE
18 chemin des Aulx
1228 Plan-les-Ouates
Switzerland

T +41 (0)22 308 93 60
F +41 (0)22 308 93 61

SELEXIS USA
655, Montgomery St. STE 540
San Francisco, CA 94111
USA

T +1 415 273 51 41
F +1 415 837 32 04

- more-

Selexis SA to Partner at BIO 2006 page 2

About Selexis

Selexis is a privately held biotechnology company dedicated to the development of expert services and innovative technologies for comprehensive and rapid solutions for stable, high yield mammalian cell line development and protein manufacturing for therapeutic drugs. The Company's unique seven step process, which includes Selexis' fourth generation patented MARtech™, reduces traditional cell line development (DHFR) from 12 months to 3 months (after transfection to isolating cell clones) without any change in the scale-up process. For more information please visit <http://www.selexis.com>

This news release contains forward-looking statements that involve a number of known and unknown risks and uncertainties. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. These statements are only predictions and actual events or results in future periods may differ materially from what is currently anticipated. In particular, we cannot assure you that we will be able to successfully develop or commercialize products based on our technology, particularly in light of the significant uncertainty inherent in developing drug delivery products, conducting clinical trials and obtaining regulatory approvals, that our technologies will prove to be safe and effective, that our joint ventures or our collaborations with other companies in the U.S. and abroad will successfully develop products or become profitable, that our business strategy will be successful or that we will be able to carry out our plans for 2007.

MARtech™ is a trademark of Selexis, SA.

MEDIA CONTACT:

Robert Meister
602-953-1716
robert.meister@selexis.com

MORE INFORMATION:

EUROPE
Igor Fisch, Ph.D.
41 (0)22 308 93 60
igor.fisch@selexis.com

UNITED STATES
Cori Gorman, Ph.D., M.B.A.,
415-273-5141
cori.gorman@selexis.com

###